IT, SharePoint Administrator & IT Specialist

Summary

This role serves as Castle Biosciences' primary SharePoint Administrator, owning the configuration, governance, and day-to-day administration of the organization's SharePoint Online environment. In addition, secondary responsibilities include broader IT duties, as delegated by IT management. This position is also responsible for the coordination, implementation, execution, and completion of specific IT duties. This role will spend the most time serving as the primary administrator for Castle Biosciences' SharePoint Online environment, developing IT and end-user technical training, and providing ad-hoc IT project support.

Job description

Requirements

• Bachelor's degree in information technology, related field, or related experience in lieu of education
• 3+ years hands-on experience administering SharePoint Online (site collections, permissions, governance, and workflows)
• At least 2 years of experience in systems (hardware and software) support
• At least 2 years of experience in education and/or corporate training
• Knowledge of IT principles, concepts, and methods
• Knowledge of systems testing and evaluation principles, methods, and tools
• Knowledge of IT security principles and methods
• Knowledge of Internet technologies and/or emerging information technologies

Benefits

• Annual bonus potential
• Paid time off
• Paid holidays
• 401(k) with company match
• Health care plan options
• Company HSA contribution
• Company stock grant

Company overview

Castle Biosciences (Nasdaq: CSTL) is a leading molecular diagnostics company that develops and commercializes innovative tests to guide patient care decisions. Founded in 2008 and headquartered in Friendswood, Texas, the company focuses primarily on dermatologic and gastroenterological diseases, with a mission to transform disease management through personalized, clinically actionable solutions. Castle's proprietary portfolio includes five commercial tests targeting unmet clinical needs in dermatologic cancers, Barrett's esophagus, and uveal melanoma. Their flagship product, DecisionDx®-Melanoma, is a gene expression profile test that predicts metastasis risk in cutaneous melanoma patients. The company also markets TissueCypher® for Barrett's esophagus, DecisionDx®-SCC for squamous cell carcinoma, MyPath® Melanoma for lesion characterization, and DecisionDx®-UM for uveal melanoma staging. With laboratory operations in Phoenix, Arizona and Pittsburgh, Pennsylvania, Castle Biosciences employs advanced molecular technologies to provide physicians with objective data for more confident treatment planning. The company reported $83 million in Q3 2025 revenue and has demonstrated strong growth in its core testing franchises, positioning itself as a significant player in the precision diagnostics market.